The time is now for the scientific community to come together to respond to the challenges of reproducibility and to be part of the solution.

It takes the ingenuity and hard work of the entire research community to move science forward. We build on the ideas and results of our peers to discover new avenues of investigation that in turn inspire ideas for others to advance.

In this way, every new publication acts as a stepping stone, paving the way to a clear and reliable path towards solving a particular scientific problem. Countless diseases have yielded to this approach over the past 100 years, which is a testament both to the expertise and resourcefulness of the community and the strength of its methodology.

Recently, however, there have been reports in journals such as *Nature* and *Science*, stating that the published literature is becoming less reproducible. These reports suggest that the methods that have served us well in the past may now be failing to faithfully guide us.

As a company rooted in science, we are troubled by these reports. Our mission has always been to produce and rigorously validate our products in-house, so they will work dependably in your experiments and be useful to the important experiments they support. Our approach to product development was affirmed by our peers who ranked us as the number one company for reproducibility, sensitivity, specificity and technical support in 2015*. We were honored to be so recognized, and we feel strongly that this recognition comes with a responsibility to act as a leader in addressing the growing reproducibility crisis.

To this end, Cell Signaling Technology is partnering with the Global Biological Standards Institute (GBSI) as well as representatives from industry and the manufacturing, publishing and academic fields. This group is hosting an online discussion with the community, this summer, to generate as many opinions and ideas from the community as it can. The group will then convene this September to review the fruits of the online discussion, draft consensus definitions of reproducibility and its underlying causes, and offer technological and process-oriented solutions.

The reproducibility crisis is undoubtedly a complicated problem, but the challenge is not insurmountable. This is especially true if we address the problem the way we would any other: head-on and as a community.

Together, we can create a means to do better; we can strengthen our faith in the published literature and be confident in our ability to advance biomedical science.

We invite you to join the discussion

www.cellsignal.com/GBSI

Sincerely,

Roberto Polakiewicz

Roberto Polakiewicz, Ph.D.
Chief Scientific Officer
Cell Signaling Technology

*2015 Biocompare Antibody Market Report
As a company rooted in science we are committed to producing and rigorously validating our products in house. This ensures they will work in your experiments and be worthy of the important research efforts they support.

We are proud to be recognized by scientists for our efforts to be leaders in key validation areas.*

*#1 Rank: 2015 Biocompare Antibody Market Report • www.cellsignal.com/rooted
Introducing the NEBNext Direct™ Cancer HotSpot Panel

Using a unique approach, the NEBNext Direct Cancer HotSpot Panel enriches for 190 common cancer targets from 50 genes prior to next generation sequencing. Combining a novel method for hybridization-based target enrichment with library preparation, the NEBNext Direct technology reduces processing time and minimizes sample loss. Ideal for automation, NEBNext Direct enables highly-specific deep sequencing of genomic regions of interest for the discovery and identification of low frequency variants from challenging sample types.

Visit NEBNextDirect.com to learn more and to inquire about sampling this product.
Be Among the First to Publish in *Science Robotics*

*Science Robotics* is a unique journal created to help advance the research and development of robotics for all environments. *Science Robotics* will provide a much-needed central forum to share the latest technological discoveries and to discuss the field’s critical issues.

Join in the excitement for the Fall 2016 debut!
DOES YOUR LAB SEEK TO UNDERSTAND MECHANISMS OF DRUG RESISTANCE OR DISEASE PATHOLOGY?

myIDP: A career plan customized for you, by you.

Features in myIDP include:

- Exercises to help you examine your skills, interests, and values.
- A list of 20 scientific career paths with a prediction of which ones best fit your skills and interests.
- A tool for setting strategic goals for the coming year, with optional reminders to keep you on track.
- Articles and resources to guide you through the process.
- Options to save materials online and print them for further review and discussion.
- Ability to select which portion of your IDP you wish to share with advisors, mentors, or others.
- A certificate of completion for users that finish myIDP.

Visit the website and start planning today!

myIDP.sciencecareers.org
ICP-OES Spectrometer Software
Neo software for inductively coupled plasma-optical emission spectroscopy (ICP-OES) spectrometers is designed to facilitate method development, samples measurements, and results management. A high dynamic range detection mode is integrated for standard measurement, advanced quality control protocols, and retrospective analysis with respect to the integrity of raw results to match with good laboratory practices requirements. For ease of use, ICP Neo displays all information on a single screen. Method development features include a visual display of interference-free lines using the S1 wavelengths database. Full automation is possible with a Smart Rinse feature for rinse efficiency monitoring between two samples, limits on correlation coefficient and recalculated concentrations, and quality control procedures that are fully EPA compliant. ICP Neo is Microsoft Windows compatible; CPU05 electronics are required. Basic training is performed by a trained service engineer. Researchers can use the software and perform samples analysis as soon as installation is completed.

Horiba Scientific
For info: 732-494-8660
www.horiba.com/scientific

Pulsed Flame Photometric Detector
The OI Analytical 5383 Pulsed Flame Photometric Detector (PFPD) is ideal for petrochemical, environmental lab, and food and beverage applications. Now in its second generation, the detector features improvements in electronics and signal processing, delivering higher selectivity and higher sensitivity. When mounted in a gas chromatograph (GC) or GC/MS, the 5383 gives chemists the ability to specifically determine and selectively analyze low levels of sulfur, phosphorus, and 26 other analytes of interest. New, intuitive, easy-to-use software provides a powerful tool for configuration, optimization, and analysis. The 5383 offers greater ease of use, improved analysis capabilities, and a compact, modular design that saves bench space while maintaining the specificity, reliable technology, and cost-efficient, time-saving features that distinguished its predecessor.

Xylem
For info: 978-778-1010
www.xylem.com

Constitutional Array
The addition of research-validated single nucleotide polymorphism (SNP) probes to the CytoSure Constitutional v3 array enables it to do exon-level copy number variation (CNV) and loss of heterozygosity (LOH) detection for comprehensive genetic analysis of developmental delay disorders. The CytoSure Constitutional v3 array content covers 502 targeted genes, with high probe density across the most biologically relevant regions, enabling the detection of single-exon aberrations. With the addition of SNP probes on the new CytoSure Constitutional v3 +LOH array, a broader range of copy-neutral genetic factors can be investigated on a single array, including LOH and uniparental disomy. The SNP probe coverage also functions as an additional validation of CNVs, reducing the need to perform follow-up investigations. Powerful data analysis and interpretation of these advanced arrays is also streamlined with CytoSure Interpret Software, which is provided with each array alongside full on-site training.

OxfordGene Technology
For info: +44-(0)-1865-856826
www.ogt.com

Biosimilar Assays
A range of ready-to-use assays now exists for testing Actemra, Stelara, and Lucentis biosimilars. The new assays allow biopharma manufacturers to generate accurate comparability results rapidly and cost-effectively. The new assays available include Actemra IL-6R Neutralization Bioassays; an Actemra IL-6R Binding ELISA; Stelara IL-12/IL-23 Binding Assays; a Stelara C1q Binding Assay; a Stelara Neutralization Bioassay; as well as Lucentis VEGF Binding Assays and a Lucentis VEGF Neutralization Bioassay. The availability of prequalified, off-the-shelf assays provides biosimilar developers the opportunity to test a wide range of biosimilars quickly and economically, utilizing assays from just one trusted supplier. Sartorius Stedim BioOutsource, which launched these assays, has its own in-house R&D department and is continually adding to its portfolio of assays. If an assay is not listed, scientists can contact the firm to discuss its availability or use the company’s expert services to configure an assay to meet their specific requirements.

Sartorius Stedim Biotech
For info: +44-(0)-141-946-4222
www.sartorius.com
want new technologies?

antibodies
apoptosis
biomarkers
cancer
cytometry
data
diseases
DNA
epigenetics
genomics
immunotherapies
medicine
microbiomics
microfluidics
microscopy
neuroscience
proteomics
sequencing
toxicology
transcriptomics

watch our webinars

Learn about the latest breakthroughs, new technologies, and ground-breaking research in a variety of fields. Our expert speakers explain their quality research to you and answer questions submitted by live viewers.

VIEW NOW! webinar.sciencemag.org

Science
AAAS

Brought to you by the Science/AAAS Custom Publishing Office

@SciMagWebinars